<DOC>
	<DOCNO>NCT01973738</DOCNO>
	<brief_summary>Although two kind selective estrogen receptor modulator ( SERM ) : raloxifene ( RLX ) bazedoxifene ( BZA ) , difference still unclear . In study , plan compare clinical efficacy safety RLX BZA .</brief_summary>
	<brief_title>Comparison Between Raloxifene Bazedoxifene</brief_title>
	<detailed_description>Selective estrogen receptor modulator ( SERM ) important option postmenopausal osteoporosis . There two SERM approve Japan treatment postmenopausal osteoporosis woman increase risk fracture . One raloxifene ( RLX ) , bazedoxifene ( BZA ) . There report concern clinical efficacy safety data . In study , plan compare clinical efficacy safety RLX BZA . The main objective study reveal effect RLX BZA bone mineral density , bone turnover marker , bone quality marker .</detailed_description>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Postmenopausal woman Patients could use SERM</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>raloxifene</keyword>
	<keyword>bazedoxifene</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>bone turnover marker</keyword>
	<keyword>bone quality</keyword>
</DOC>